bioMérieux (BIM) H1 2025 earnings summary

Executive summary

• Achieved 9.4% organic sales growth in H1 2025, reaching €2,044 million, led by molecular diagnostics, industrial applications, and double-digit gains in BIOFIRE® and SPOTFIRE® panels.

• Profitability improved with CEBIT up 21.5% to €372 million (18.2% margin), supported by efficiency gains and the GO-28 plan.

• Free cash flow more than tripled to €170 million, reflecting EBITDA growth and working capital improvements.

• Net income declined 25% to €161 million due to a €146 million impairment on Reveal technology; excluding this, net income rose 45%.

• Multiple new product launches and strategic acquisitions (SpinChip, Day Zero Diagnostics, Neoprospecta) completed; significant progress on CSR objectives, including a 27% reduction in greenhouse gas emissions.

Financial highlights

• Net sales reached €2,044 million, up 9.4% like-for-like and 7.5% as reported, with a €34 million negative currency effect.

• Gross profit margin improved to 57.1% of sales (up 80bps), driven by favorable product mix and pricing.

• EBITDA reached €495 million (24.2% of sales), up 17% year-over-year.

• SG&A expenses rose 7.7%, including an €8 million one-off for the MyShare employee plan.

• R&D expenses were €249 million (12.2% of sales), up 2.8% like-for-like, focused on molecular and microbiology.

Outlook and guidance

• 2025 organic sales growth guidance revised to 6–7.5% due to China market decline.

• CEBIT growth guidance raised to 12–18% for 2025, with a negative currency effect of about €25 million.

• Tariff impacts estimated at €5–10 million in 2025 and €35 million in 2026, with mitigation actions underway.

• CapEx guidance lowered to 9% of sales for the year.

• FX impact on FY25 CEBIT estimated at –€25 million.